These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 5386074)

  • 21. [The conservative treatment of thrombophlebitis of the surface veins of the lower extremities].
    Kirienko AI; Koshkin VM
    Ter Arkh; 1995; 67(4):53-5. PubMed ID: 7784978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [External gel treatment of venous syndromes].
    Romeo S; Spinella G
    Clin Ter; 1978 Feb; 84(3):245-52. PubMed ID: 346297
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry.
    Crespo EM; Oliveira GB; Honeycutt EF; Becker RC; Berger PB; Moliterno DJ; Anstrom KJ; Abrams CS; Kleiman NS; Moll S; Rice L; Rodgers JE; Steinhubl SR; Tapson VF; Granger CB; Ohman EM;
    Am Heart J; 2009 Apr; 157(4):651-7. PubMed ID: 19332191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Results of prolonged anticoagulant therapy of patients with coronary cardiosclerosis and angina pectoris].
    Kibarskis KhKh
    Klin Med (Mosk); 1966 Mar; 44(3):66-9. PubMed ID: 5993542
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of potassium and tris-aspartate on heparin-induced serum free-fatty-acids evaluation, in man.
    Gavrilescu S; Danciu T; Fiat F; Pop T
    Agressologie; 1970; 11(6):501-5. PubMed ID: 5502791
    [No Abstract]   [Full Text] [Related]  

  • 26. [Early use of heparin and thrombolytic drugs in thrombosis and embolism of different localization].
    Bukhalovskiĭ IN; Morar' DI
    Sov Med; 1980; (3):114-5. PubMed ID: 6445597
    [No Abstract]   [Full Text] [Related]  

  • 27. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of lipoprotein lipase and effect of heparin on blood lipids in exogenous obesity.
    Miturzyńska-Stryjecka H
    Pol Med J; 1967; 6(6):1459-65. PubMed ID: 5582674
    [No Abstract]   [Full Text] [Related]  

  • 29. [Control of fat clearance insufficiency in hyperlipemic atherosclerosis].
    Zeller W; Christ F
    Med Klin; 1966 Jan; 61(4):136-9. PubMed ID: 5983158
    [No Abstract]   [Full Text] [Related]  

  • 30. A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype.
    Ray KK; Francis S; Crossman DC
    J Thromb Haemost; 2005 Feb; 3(2):287-91. PubMed ID: 15670034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical experimentation with a new cardioactive combination: Teostellarid].
    Cavazzuti F; Chiarato G
    Minerva Cardioangiol; 1969 Jun; 17(6):405-18. PubMed ID: 5394080
    [No Abstract]   [Full Text] [Related]  

  • 32. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is there a drug interaction between heparin and molsidomine?].
    Weimer M; Pizzulli L; Reichert H; Lüderitz B
    Med Klin (Munich); 1994 Jul; 89 Suppl 2():45-6. PubMed ID: 7968902
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapy of coronary insufficiency].
    De Matteis F
    G Batteriol Virol Immunol Ann Osp Maria Vittor Torino; 1970; 63(9):551-8. PubMed ID: 5518365
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effect of heparin on blood clot retraction in different forms of coronary disease].
    Novitskiĭ VS
    Vrach Delo; 1969 May; 5():139-40. PubMed ID: 5368870
    [No Abstract]   [Full Text] [Related]  

  • 36. A contribution to the prophilaxis of coronary heart insufficiency in advanced age.
    Dobrowolski L
    G Gerontol; 1966 Oct; 14(10):989-96. PubMed ID: 5993796
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Basic problems in coronary revascularization].
    Biffani G
    G Ital Cardiol; 1983; 13(4):324-9. PubMed ID: 6224714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Heparin therapy and coronary cardiopathy].
    Branzi A; Melandri G
    Cardiologia; 1996 Dec; 41(12):1147-54. PubMed ID: 9064212
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of anticoagulant therapy on the patency of aorto-coronary bypass graft (author's transl)].
    Sasaki T; Yokoyama H; Yamaguchi T; Yoshino K; Kagaya H
    Kyobu Geka; 1981 Feb; 34(2):110-2. PubMed ID: 6974794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.